Regenxbio Inc (NASDAQ:RGNX) Given Consensus Recommendation of “Buy” by Analysts

Shares of Regenxbio Inc (NASDAQ:RGNX) have earned a consensus rating of “Buy” from the twelve research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $87.00.

RGNX has been the subject of several research reports. Svb Leerink raised Regenxbio from an “underperform” rating to a “market perform” rating and decreased their target price for the stock from $38.00 to $37.00 in a research report on Tuesday, August 20th. Morgan Stanley set a $84.00 target price on Regenxbio and gave the stock a “buy” rating in a research report on Monday, July 15th. Zacks Investment Research lowered Regenxbio from a “hold” rating to a “sell” rating in a research report on Thursday, September 19th. Raymond James initiated coverage on Regenxbio in a research report on Thursday, June 13th. They issued an “outperform” rating for the company. Finally, Leerink Swann raised Regenxbio from an “underperform” rating to a “market perform” rating in a research report on Tuesday, August 20th. They noted that the move was a valuation call.

In related news, CEO Kenneth T. Mills sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $39.75, for a total transaction of $397,500.00. Following the completion of the transaction, the chief executive officer now owns 251,000 shares of the company’s stock, valued at approximately $9,977,250. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Kenneth T. Mills sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $37.55, for a total value of $563,250.00. Following the transaction, the insider now directly owns 261,000 shares of the company’s stock, valued at approximately $9,800,550. The disclosure for this sale can be found here. Insiders sold a total of 50,486 shares of company stock valued at $2,183,662 in the last three months. Corporate insiders own 13.80% of the company’s stock.

A number of hedge funds have recently bought and sold shares of RGNX. Berman Capital Advisors LLC increased its position in Regenxbio by 41.6% during the 2nd quarter. Berman Capital Advisors LLC now owns 1,133 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 333 shares in the last quarter. NEXT Financial Group Inc bought a new position in Regenxbio during the 2nd quarter valued at approximately $69,000. SG3 Management LLC bought a new position in Regenxbio during the 1st quarter valued at approximately $115,000. Royal Bank of Canada increased its position in Regenxbio by 36.2% during the 2nd quarter. Royal Bank of Canada now owns 3,910 shares of the biotechnology company’s stock valued at $201,000 after buying an additional 1,040 shares in the last quarter. Finally, Virginia Retirement Systems ET AL bought a new position in Regenxbio during the 2nd quarter valued at approximately $216,000. 79.40% of the stock is owned by institutional investors.

NASDAQ RGNX traded down $1.08 on Monday, hitting $37.41. The company’s stock had a trading volume of 466,489 shares, compared to its average volume of 560,890. Regenxbio has a 52-week low of $30.38 and a 52-week high of $73.81. The company has a current ratio of 14.58, a quick ratio of 14.58 and a debt-to-equity ratio of 0.01. The company’s 50-day simple moving average is $35.79 and its 200 day simple moving average is $45.72. The firm has a market cap of $1.38 billion, a P/E ratio of 15.72 and a beta of 0.82.

Regenxbio (NASDAQ:RGNX) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.46. Regenxbio had a negative return on equity of 15.39% and a negative net margin of 88.57%. The business had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $5.45 million. During the same quarter last year, the business posted $0.30 EPS. The business’s revenue was down 80.3% on a year-over-year basis. On average, research analysts forecast that Regenxbio will post -2.85 EPS for the current fiscal year.

Regenxbio Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Recommended Story: Asset Allocation

Analyst Recommendations for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.